Tresiba for Type 2
Two studies suggest that ultra-long-acting insulin degludec (Tresiba) is heart safe and may help people with type 2 diabetes improve their blood glucose management. In one two-year study of 7,637 people, those taking degludec had fewer heart attacks or strokes than those using insulin glargine (Lantus), lower fasting blood glucose levels, and fewer episodes of severe low blood glucose (hypoglycemia). In the other study, involving over 500 people with diabetes who weren’t hitting glucose targets with once-daily basal (background) insulin, a single combined injection of degludec and the glucose-lowering drug liraglutide (Xultophy) controlled blood glucose as well as four injections of a basal-bolus regimen—with less weight gain and hypoglycemia.
Source: American Diabetes Association 77th Scientific Sessions